Drug Profile
Olafertinib - Checkpoint Therapeutics/Suzhou NeuPharma
Alternative Names: CK-101; RX 518Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Suzhou NeuPharma
- Developer Checkpoint Therapeutics; Suzhou NeuPharma
- Class Amides; Aniline compounds; Antibodies; Antineoplastics; Fluorobenzenes; Piperazines; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
Most Recent Events
- 30 Jun 2022 Checkpoint Therapeutics completes a phase I/II trial in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Poland, New Zealand, Thailand (PO) (NCT02926768) (EudraCT2017-001265-24)
- 08 Jun 2022 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy) (PO), prior to June 2022 (Checkpoint Therapeutics pipeline, June 2022)
- 08 Apr 2022 Checkpoint Therapeutics has patents pending for olafertinib in US